In the present in vitro study, we examined the effect of the compound -elemene on the response of KB-C2 cells overexpressing the ABCB1 transporter to specific antineoplastic compounds. The MTT assay was used to determine the effects of -elemene in combination with other anticancer drugs on ABCB1-overexpressing cancer cell lines. Furthermore, we used [H-3]-paclitaxel accumulation, efflux assay, immunofluorescence experiments, western blot assays and docking analysis to ascertain the mechanism of action of -elemene. The incubation of KB-C2 cells overexpressing ABCB1 transporter with -elemene (100 M) significantly augmented the antineoplastic efficacy of colchicine, vinblastine and paclitaxel when compared to KB-C2 cells incubated with these drugs alone. In HEK293 cells overexpressing the ABCB1 transporter, -elemene significantly increased the cytotoxicity of paclitaxel. In addition, 100 M of -elemene significantly increased the accumulation of [H-3]-paclitaxel and this was due to a decrease in [H-3]-paclitaxel efflux when compared to controls. The incubation of KB-C2 cells with -elemene (100 M) for 72 h did not significantly alter the expression of ABCB1 protein levels. Immunofluorescence experiments indicated that -elemene did not significantly alter the subcellular localization of the ABCB1 transporter. Docking analysis indicated that -elemene binds to the drug-binding site of ABCB1 transporter. Finally, -elemene at 100 M partially (similar to 50%) increased the sensitivity of the BCRP-overexpressing cell line, NCI-H460/MX20, to mitoxantrone, but -elemene did not significantly alter the resistance of MRP1-transfected HEK293/MRP1 cells to vincristine. Overall, our in vitro findings indicated that -elemene potentiates the cytotoxic effects of various antineoplastic drugs in cell lines overexpressing the ABCB1 transporter and that this is due to the inhibition of the efflux component of the ABCB1 transporter.